Sarepta’s Eteplirsen and FDA’s “Breakthrough Therapy” Designation: A Perfect Fit?
This article was originally published in RPM Report
Executive Summary
Strong early efficacy data for Sarepta’s Duchenne therapy has investors speculating about whether the drug can qualify for accelerated approval. But maybe the first step should be use of the new FDA “Breakthrough” designation.